DK2152692T3 - Forbindelser med anti-cancer aktivitet - Google Patents

Forbindelser med anti-cancer aktivitet Download PDF

Info

Publication number
DK2152692T3
DK2152692T3 DK08829410.3T DK08829410T DK2152692T3 DK 2152692 T3 DK2152692 T3 DK 2152692T3 DK 08829410 T DK08829410 T DK 08829410T DK 2152692 T3 DK2152692 T3 DK 2152692T3
Authority
DK
Denmark
Prior art keywords
amino
optionally substituted
dione
trifluoromethyl
methyl
Prior art date
Application number
DK08829410.3T
Other languages
English (en)
Inventor
Takumi Kawabe
Machiyo Ishigaki
Takuji Sato
Sayaka Yamamoto
Yoko Hasegawa
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Application granted granted Critical
Publication of DK2152692T3 publication Critical patent/DK2152692T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (15)

1. Forbindelse, der har formlen
Struktur (II) hvor R1 og R2 er uafhængigt af hinanden valgt blandt alkyl, substitueret alkyl, eventuelt substitueret alkoxy, eventuelt substitueret alkylthio, eventuelt substitueret aryloxy, eller eventuelt substitueret arylthio, hvor når X ikke er O, kan R1 og R2 også være del af en cyklisk alkylen kæde som danner en sammensplejset ringstruktur; X er O, S eller NR3; når X er NR3, er Ar ikke phenyl; Aryl eller substitueret aryl i den eventuelt substituerede aryloxy eller eventuelt substituerede arylthio indbefatter carbocyklisk aryl, heterocyklisk aryl, monocyklisk aryl, polycyklisk aryl og aryl sammensplejset med non-aryl (non-aromatiske) ringe; R3 er H, alkyl, substitueret alkyl, eventuelt substitueret acyl, eller som del af en ringstruktur, der forbinder N- til Ar-ringen; A er N eller CH; B er CR8; og R5, R7, R8 og R9 er uafhængigt af hinanden valgt blandt H, alkyl, substitueret alkyl, halogen, eventuelt substitueret aryl, eventuelt substitueret heteroaryl, eventuelt substitueret alkoxy, eventuelt substitueret aryloxy, cyano, nitro, eventuelt substitueret alkylthio, eventuelt substitueret alkylsulfinyl, eventuelt substitueret alkylsulfonyl, eventuelt substitueret arylthio, eventuelt substitueret acyl, eventuelt substitueret amino, carboxyl, eventuelt substitueret alkoxycarbonyl, eventuelt substitueret carbamoyl, hvor R og R7, eller R og R8, eller R og R9 kan være del af en cyklisk alkylengruppe, der danner en sammensplejset ringstruktur; eller et salt deraf; yderligere, hvor forbindelsen ikke har den følgende struktur:
2. Forbindelse ifølge krav 1, hvor én af R1 og R2 er methyl, og den anden af R1 og R2 er alkyl eller alkyl substitueret med alkoxy, hydroxy, carboxy, alkoxycarbonyl, eventuelt substitueret carbamoyl eller eventuelt substitueret cyklisk aminocarbonyl.
3. Forbindelse ifølge krav 1, hvor både R1 og R2 er del af en cyklisk alkylenkæde, der danner en sammensplejset ringstruktur.
4. Forbindelse ifølge krav 1, hvor X er NR3, hvor R3 er H, alkyl eller acyl.
5. Forbindelse ifølge krav 1, hvor R5, R7, R8 og R9 er uafhængigt af hinanden valgt blandt H, alkyl, halogen, trifluormethyl, eventuelt substitueret phenyl, alkoxy, cyano, eller alkyl substitueret med phenyl, eventuelt substitueret amino, eventuelt substitueret cyklisk amino eller acyloxy.
6. Forbindelse ifølge krav 1, hvor to tilstødende substitutioner R5 og R7, eller R8 og R9 danner en sammensplejset og substitueret benzenring.
7. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående af tert-butyl 3-(l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-methyl-2,5- dioxoazolin-3-yl) propanoat (S01860); ethyl 3-(l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-methyl -2,5-dioxoazolin- 3-yl) propanoat (S01861), 3,4-dimethyl-l-[(4,7,8-trichlor(2-quinolyl))amino]azolin-2,5-dion (S01078), l-[(8-brom-4-chlor(2-quinolyl))amino]-3,4-dimethylazolin-2,5-dion (SO 1247), tert-butyl 4-({2-[(3,4-dimethyl-2,5-dioxoazolinyl)amino]-7-brom-4-quinolyl)-methyl) piperazincarboxylat (S01589), methyl 3-(l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-methyl-2,5-dioxoazolin-3-yl)propanoat (S01648), 3-(l-{[6-chlor-5-(trifluormethyl)(2-pyridyl]amino}-4-methyl-2,5-dioxoazolin-3-yl)-N-methoxy-N-methylpropanamid (S01796), l-{[7-brom-4-({4-[(2-methoxyphenyl)carbonyl]piperazinyl}methyl)(2-quinolyl)] amino}-3,4-dimethylazolin-2,5-dion (S01879), l-{[3-brom-6-chlor-5-(trifluormethyl)(2-pyridyl)]amino>-3,4-dimethylazolin-2,5-dion (S01981), l-{[6-chlor-3-(trifluormethyl)(2-pyridyl)]amino}-3,4-dimethylazolin-2,5-dion (S00109), l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]methylamino}-3,4-dimethylazolin-2,5-dion (S00170), l-{[6-brom-5-(trifluormethyl)(2-pyridyl)]methylamino}-3,4-dimethylazolin-2,5-dion (S01007), l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino)--4-methyl-3-(3-methylbutyl) azolin- 2,5-dion (S01554), l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino)--3-(methoxymethyl)-4-methylazolin-2,5-dion (S01599), l-{[7,8-dichlor-4-(trifluormethyl)(2-quinolyl)]amino}-3,4-dimethylazolin-2,5-dion (S01455), 3-(l-{[6-chlor-5-(trifluormethyl)(2-pyndyl)]annino}-4-methyl-2,5-dioxoazolin-3-yl)-Ν,Ν-diethylpropanannid (S01711), diethyl 2-[(l-{{[6-chlor-5-(trifluormethyl)(2-pyndyl)]annino>-4-methyl-2,5-dioxoazolin-3-yl)methyl]propan-1,3-dioat (S01712), N-(tert-butyl)-3-(l-{[6-chlor-5-(trifluornnethyl)(2-pyndyl)]annino}-4-nnethyl-2,5-dioxoazolin-3-yl)propanamid (S01758), l-{[7-brom-4-({4-[(3-methoxyphenyl)carbonyl]piperazinyl}nnethyl)(2-quinolyl)]amino>-3,4-dimethylazolin-2,5-dion (S01925), l-{[6-brom-5-(trifluornnethyl)(2-pyndyl)]annino}-3,4-dinnethylazolin-2,5-dion (S00994), l-[(4,8-dichlor(2-quinolyl))amino]-3,4-dinnethylazolin-2,5-dion (SO 1005), 3.4- dimethyl-l-{ [6-phenyl-5-(trifluornnethyl)(2-pyndyl)]annino}azolin-2,5-dion (S01266), l-{[6-chlor-5-(trifluornnethyl)(2-pyridyl)]annino}-3-(hydroxynnethyl)-4-nnethylazolin- 2,5-dion (S01470), N-(3,4-dimethyl-2,5-dioxoazolinyl)-N-[6-chlor-5-(trifluornnethyl)(2-pyndyl)]acetannid (S01473), l-{[7-brom-4-({4-[(2-chlorphenyl)carbonyl]piperazinyl}-nnethyl)(2-quinolyl)]annino)-- 3,4-dimethylazolin-2,5-dion (S01878), 3-(l-{[6-chlor-5-(trifluornnethyl)(2-pyndyl)]annino}-4-nnethyl-2,5-dioxoazolin-3-yl)-N-methylpropanamid (S01883), l-[(8-chlor(2-quinolyl))amino]-3,4-dinnethylazolin-2,5-dion (S00585), 3.4- dimethyl-l-[(3,4,5-trichlorphenyl)amino]azolin-2,5-dion (S00832), 3.4- dimethyl-l-{[4-(trifluornnethyl)(2-quinolyl)]annino}azolin-2,5-dion (S00873), l-[(7-brom-4-chlor(2-quinolyl))amino]-3,4-dinnethylazolin-2,5-dion (SO 1311), l-{[6-(3-chlor-4-fluorphenyl)-5-(tnfluornnethyl)(2-pyndyl)]annino>-3,4- dimethylazolin-2,5-dion (S01313), 3.4- dimethyl-l-{[6-(2-methylpropyl)-5-(trifluornnethyl)(2-pyndyl)annino}azolin-2,5-dion (S01457), l-{[6-chlor-4-(trifluornnethyl)(2-pyridyl)]annino}-3,4-dinnethylazolin-2,5-dion (S01737), Methyl 3-(l-{[4-({4-[(tert-butyl)oxycarbonyl]piperazinyl}methyl)-7-bronn(2-quinolyl)]amino}-4-methyl-2,5-dioxoazolin-3-yl)propanoat (S01865), l'({4-[(4-{[4-(dimethylamino)phenyl]carbonyl)-piperazinyl)nnethyl]-7-bronn(2-quinolyl)}amino)-3,4-dimethylazolin-2,5-dion (S01880), l-[(3-chlorisoquinolyl)annino]-3,4-dinnethylazolin-2,5-dion (SO 1098), l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]annino}-3-ethyl-4-nnethylazolin-2,5-dion (S01553), l-{[4-chlor-6-phenyl-5-(trifluormethyl)(2-pyridyl)]amino}-3,4-dimethylazolin-2,5-dion (S01734), N-[l-({2-[(3,4-dimethyl-2,5-dioxoazolinyl)amino]-7-bronn(4-quinolyl)}methyl) pyrrolidin-3-yl](tert-butoxy)carboxamid (S01864), 1- {[7-brom-4-({4-[(4-fluorphenyl)carbonyl]piperazinyl}methyl)(2-quinolyl)]amino}- 3.4- dimethylazolin-2,5-dion (S01877), 6-[(3,4-dimethyl-2,5-dioxoazolinyl)ami no]-3-(trifluormethyl)pyndin-2-carbonitnl (S01475), 2- {[6-chlor-5-(tnfluormethyl)-2-pyndyl]amino}-4,5,6,7-tetrahydroisoindol-l,3-dion (S00186), l-{[4-brom-3-(tnfluormethyl)phenyl]amino}-3,4-dimethylazolin-2,5-dion (S00516), l-[(4-chlomaphthyl)amino]-3,4-dimethylazolin-2,5-dion (S00738), l-[(4-chlor-6-methyl(2-quinolyl))amino]-3,4-dimethylazolin-2,5-dion (S00935), l-[(4-bromnaphthyl)amino]-3,4-dimethylazolin-2,5-dion (S00942), l-{[7-brom-4-(hydroxymethyl)(2-quinolyl)]amino}-3,4-dimethylazolin-2,5-dion (S01037), {2-[(3,4-dimethyl-2,5-dioxoazolinyl)amino]-7-brom-4-quinolyl}-methylacetat (S01047), l-{[8-chlor-4-(4-methoxyphenyl)(2-quinolyl)]amino}--3,4-dimethylazolin-2,5-dion (S01191), l-[(4-chlorbenzo[h]quinolin-2-yl)amino]-3,4-dimethylazolin-2,5-dion (SO 1207), l-[(7-brom-4-{[4-benzylpiperazinyl]methyl>(2-quinolyl))amino]-3,4-dimethylazolin- 2.5- dion (S01268), l-{[6-(4-chlorphenyl)-5-(trifluormethyl)(2-pyridyl)]amino}-3,4-dimethylazolin-2,5-dion (S01371), 3.4- dimethyl-l-{ [6-(4-methylphenyl)-5-(trifluormethyl) (2-pyndyl)]amino>azolin- 2.5- dion (S01393), l-{[6-(3-chlorphenyl)-5-(tnfluormethyl)(2-pyridyl)]amino}-3,4-dimethylazolin-2,5-dion (S01474), l-{[6-chlor-5-(tnfluormethyl)(2-pyridyl)]methylamino}-3-(methoxymethyl)-4-methylazolin-2,5-dion (S01600), phenylmethyl4-({2-[(3,4-dimethyl-2,5-dioxoazolinyl)amino]-7-brom-4-quinolyl> me-thyl)piperazincarboxylat (S01683), 3.4- dimethyl-1-({6-[3-(tnfluormethyl)phenyl](2-pyridyl)}amino)azolin-2,5-dion (S01691), l-[(7-brom-4-{[4-(phenylcarbonyl)piperazinyl]methyl}(2-quinolyl))amino]-3,4-dimethylazolin-2,5-dion (S01699), 3- (l-{[6-chlor-5-(tnfluormethyl)(2-pyndyl)]amino}-4-methyl-2,5-dioxoazolin-3-yl)- N-methyl-N-phenylpropanamid (S01759), 3,4-dimethyl -l-{ [6-benzyl-5-(trifluormethyl)(2-pyridyl)]annino}azolin-2,5-dion (S01762), l'{[4-({4-[(2,4-dimethylphenyl)carbonyl]piperazinyl}methyl)-7-brom(2-quinolyl)] amino>-3,4-dimethylazolin-2,5-dion (S01800), l-{[7-brom-4-({4-[(4-methoxyphenyl)carbonyl]piperazinyl}methyl)(2-quinolyl)] amino}-3,4-dimethylazolin-2,5-dion (S01801), N-[6-chlor-5-(trifluormethyl)(2-pyndyl)]-N-[4-(hydroxymethyl)-3-methyl-2,5-dioxoazolinyl]acetamid (S01820), l-[(7-brom-4-{[4-(phenylsulfonyl)piperazinyl] methyl }(2-quinolyl))amino]-3,4-dimethylazolin-2,5-dion (S01822), l-[(4-chlor-8-methyl(2-quinolyl))amino]-3,4-dimethylazolin-2,5-dion (S00871), tert-butyl 4-[({2-[(3,4-dimethyl-2,5-dioxoazolinyl)amino]-7-brom-4-quinolyl}me- thyl)amino] piperidincarboxylat (S01862), tert-butyl 4-[4-({2-[(3,4-dimethyl-2,5-dioxoazolinyl)amino]-7-brom-4-quinolyl>me-thyl)piperazinyl]piperidincarboxylat (S01928), l'[(4-{[4-(3,3-dimethylbutanoyl)piperazinyl]methyl}-7-brom(2-quinolyl))amino]- 3.4- dimethylazolin-2,5-dion (S01929), Methylethyl 3-(l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-methyl-2,5-dioxoazolin-3-yl)propanoat (S02022) Methylpropyl 3-(l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-methyl-2,5-dioxoazolin-3-yl)propanoat (S02264) tert-Butyl 2-(l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino>-4-methyl-2,5-dioxoazolin-3-yl)acetat (S02225) l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-3-(ethoxymethyl)-4-methylazolin- 2.5- dion (S02366)
3-Butyl-l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-methylazolin-2,5-dion (S03448) l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-methyl-3-[2-(2-methyl(l,3-dioxolan-2-yl))ethyl]azolin-2,5-dion (S03456) l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-3-[(2-methoxyethoxy)methyl]-4-methylazolin-2,5-dion (S03742) l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino>-4-(3-hydroxyhexyl)-3-methylazolin-2,5-dion (S03552) l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-(3-hydroxypentyl)-3-methylazolin-2,5-dion (S03745) l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-methyl-3-[(3-methylbutoxy) methyl]azolin-2,5-dion (S03405) 3-(Butoxymethyl)-l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]amino}-4-methylazolin- 2.5- dion (S03518) 3-[(3,3-Dimethylbutoxymethyl]-l-{[6-chlor-5-(trifluormethyl) (2-pyridyl)]amino)--4-methylazolin-2,5-dion (S03747) l-{[6-chlor-5-(tnfluormethyl)(2-pyridyl)]amino}-3-(2-ethoxyethyl)-4-methylazolin- 2.5- dion (S03960) l-{[6-chlor-5-(tnfluormethyl)(2-pyridyl)]amino}-4-methyl-3-[(2-methylpropoxy)methyl]azolin-2,5-dion (S03963) 3- [(2,2-Dimethylpropoxy)methyl]-l-{[6-chlor-5-(trifluormethyl) (2-pyridyl)]annino}- 4-methylazolin-2,5-dion (S03962) 4- [(l,3-Dimethylbutoxy)methyl]-l-{[6-chlor-5-(trifluormethyl) (2-pyridyl)] amino}-3-methylazolin-2,5-dion (S03964) 4-[(tert-Butoxy)methyl]-l-{[6-chlor-5-(tnfluormethyl)(2-pyndyl)]annino}-3-methylazolin-2,5-dion (S03873) l-{[6-chlor-5-(tnfluormethyl)(2-pyridyl)]annino}-4-methyl-3-[2-(2-methylpropoxy)ethyl]azolin-2,5-dion (S03955) l-{[6-chlor-5-(trifluormethyl)(2-pyridyl)]annino}-4-methyl-3-[2-(3-methylbutoxy)ethyl]azolin-2,5-dion (S03956) l-{[6-chlor-5-(trifluormethyl)(2-pyridyl]amino)-3-methyl-4-(2-propoxyethyl)azolin- 2.5- dion (S04034); og salte deraf.
8. Farmaceutisk sammensætning omfattende forbindelsen af et hvilket som helst af de foregående krav i kombination med en farmaceutisk acceptabel excipiens.
9. Anvendelse af en forbindelse, der har formlen
Struktur (II) hvor R1 og R2 er uafhængigt af hinanden valgt blandt alkyl, substitueret alkyl, eventuelt substitueret alkoxy, eventuelt substitueret alkylthio, eventuelt substitueret aryloxy, eller eventuelt substitueret arylthio, hvor når X ikke er O, kan R1 og R2 også være del af en cyklisk alkylenkæde, der danner en sammensplejset ringstruktur; X er O, S eller NR3; når X er NR3, er Ar ikke phenyl; Aryl eller substitueret aryl i den eventuelt substituerede aryloxy eller eventuelt substituerede arylthio, indbefatter carbocyklisk aryl, heterocyklisk aryl, monocyklisk aryl, polycyklisk aryl, og aryl sammensplejset med non-aryl (non-aromatiske) ringe; R3 er H, alkyl, substitueret alkyl, eventuelt substitueret acyl, eller som del af en ringstruktur, der forbinder N- til Ar-ringen; A er N eller CH; B er CR8 eller N; og R5, R7, R8 og R9 er uafhængigt af hinanden valgt blandt H, alkyl, substitueret alkyl, halogen, eventuelt substitueret aryl, eventuelt substitueret heteroaryl, eventuelt substitueret alkoxy, eventuelt substitueret aryloxy, cyano, nitro, eventuelt substitueret alkylthio, eventuelt substitueret alkylsulfinyl, eventuelt substitueret alkylsulfonyl, eventuelt substitueret arylthio, eventuelt substitueret acyl, eventuelt substitueret amino, carboxyl, eventuelt substitueret alkoxycarbonyl, eventuelt substitueret carbamoyl, hvor R5 og R7, eller R og R8, eller R og R9 kan være del af en cyklisk alkylengruppe, der danner en sammensplejset ringstruktur; eller et salt deraf; yderligere, hvor forbindelsen ikke har den følgende struktur:
til fremstilling af et lægemiddel til behandling af en celle-proliferationslidelse.
10. Anvendelse ifølge krav 9, hvor forbindelsen er som defineret i et hvilket som helst af krav 1 til 7.
11. Forbindelse, der har formlen
Struktur (II) hvor R1 og R2 er uafhængigt af hinanden valgt blandt alkyl, substitueret alkyl, eventuelt substitueret alkoxy, eventuelt substitueret alkylthio, eventuelt substitueret aryloxy, eller eventuelt substitueret arylthio, hvor når X ikke er O, kan R1 og R2 også være del af en cyklisk alkylenkæde, der danner en sammensplejset ringstruktur; X er O, S, eller NR3; når X er NR3, er Ar ikke phenyl; Aryl eller substitueret aryl i den eventuelt substituerede aryloxy eller eventuelt substituerede arylthio, indbefatter carbocyklisk aryl, heterocyklisk aryl, monocyklisk aryl, polycyklisk aryl, og aryl sammensplejset med non-aryl (non-aromatiske) ringe; R3 er H, alkyl, substitueret alkyl, eventuelt substitueret acyl, eller som del af en ringstruktur, der forbinder N- til Ar-ringen; A er N eller CH; B er CR8 eller N; og R5, R7, R8 og R9 er uafhængigt af hinanden valgt blandt H, alkyl, substitueret alkyl, halogen, eventuelt substitueret aryl, eventuelt substitueret heteroaryl, eventuelt substitueret alkoxy, eventuelt substitueret aryloxy, cyano, nitro, eventuelt substitueret alkylthio, eventuelt substitueret alkylsulfinyl, eventuelt substitueret alkylsulfonyl, eventuelt substitueret arylthio, eventuelt substitueret acyl, eventuelt substitueret amino, carboxyl, eventuelt substitueret alkoxycarbonyl, eventuelt substitueret carbamoyl, hvor R og R7, eller R7 og R8, eller R og R9 kan være del af en cyklisk alkylengruppe, der danner en sammensplejset ringstruktur; eller et salt deraf; yderligere, hvor forbindelsen ikke har den følgende struktur:
til anvendelse i behandling afen celle-proliferationslidelse.
12. Forbindelse til anvendelse ifølge krav 11, hvor forbindelsen er som defineret i et hvilket som helst af krav 1 til 7.
13. In vitro eller ex vivo fremgangsmåde til at dræbe eller at standse en uønsket-prolifererende celle forbundet med en celle-proliferationslidelse omfattende at indgive til cellen, i en mængde virkningsfuld til at modvirke G2-kontrolpunktet og/eller forårsager tilpasning til G2-cellecyklus standsning, en forbindelse, der har formlen
Struktur (II) hvor R1 og R2 er uafhængigt af hinanden valgt blandt alkyl, substitueret alkyl, eventuelt substitueret alkoxy, eventuelt substitueret alkylthio, eventuelt substitueret aryloxy, eller eventuelt substitueret arylthio, hvor når X ikke er O, kan R1 og R2 også være del af en cyklisk alkylenkæde, der danner en sammensplejset ringstruktur; X er O, S eller NR3; når X er NR3 er Ar ikke phenyl; Aryl eller substitueret aryl i den eventuelt substituerede aryloxy eller eventuelt substituerede arylthio, indbefatter carbocyklisk aryl, heterocyklisk aryl, monocyklisk aryl, polycyklisk aryl, og aryl sammensplejset med non-aryl (non-aromatiske) ringe; R3 er H, alkyl, substitueret alkyl, eventuelt substitueret acyl, eller som del af en ringstruktur, der forbinder N- til Ar-ringen; A er N eller CH; B er CR8 eller N; og R5, R7, R8 og R9 er uafhængigt af hinanden valgt blandt H, alkyl, substitueret alkyl, halogen, eventuelt substitueret aryl, eventuelt substitueret heteroaryl, eventuelt substitueret alkoxy, eventuelt substitueret aryloxy, cyano, nitro, eventuelt substitueret alkylthio, eventuelt substitueret alkylsulfinyl, eventuelt substitueret alkylsulfonyl, eventuelt substitueret arylthio, eventuelt substitueret acyl, eventuelt substitueret amino, carboxyl, eventuelt substitueret alkoxycarbonyl, eventuelt substitueret carbamoyl, hvor R5 og R7, eller R7 og R8, eller R8 og R9 kan være del af en cyklisk alkylengruppe, der danner en sammenplejset ringstruktur; eller et salt deraf; yderligere, hvor forbindelsen ikke har den følgende struktur:
14. Fremgangsmåde ifølge krav 13, hvor forbindelsen er som defineret i et hvilket som helst af krav 1 til 7.
15. Anvendelse ifølge krav 9 eller 10, forbindelse til anvendelse ifølge krav 11 eller 12 eller fremgangsmåde ifølge krav 13 eller 14, hvor celle-proliferationslidelsen er cancer eller yderligere omfattende at indgive mindst én yderligere anti-cancerbehandling.
DK08829410.3T 2007-04-11 2008-04-11 Forbindelser med anti-cancer aktivitet DK2152692T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91125807P 2007-04-11 2007-04-11
PCT/IB2008/003036 WO2009031040A2 (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity

Publications (1)

Publication Number Publication Date
DK2152692T3 true DK2152692T3 (da) 2016-09-26

Family

ID=39939984

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19167943.0T DK3567035T3 (da) 2007-04-11 2008-04-11 N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
DK08829410.3T DK2152692T3 (da) 2007-04-11 2008-04-11 Forbindelser med anti-cancer aktivitet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19167943.0T DK3567035T3 (da) 2007-04-11 2008-04-11 N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer

Country Status (18)

Country Link
US (2) US8084454B2 (da)
EP (4) EP3088397B1 (da)
JP (2) JP5635396B2 (da)
KR (1) KR101475311B1 (da)
CN (2) CN105175394B (da)
AU (1) AU2008294410B2 (da)
BR (2) BRPI0810911B1 (da)
CA (4) CA3188320A1 (da)
DK (2) DK3567035T3 (da)
ES (3) ES2732230T3 (da)
HK (1) HK1139143A1 (da)
HU (2) HUE059861T2 (da)
IL (4) IL309201A (da)
MX (2) MX2020009403A (da)
NZ (1) NZ580237A (da)
RU (1) RU2482111C2 (da)
WO (1) WO2009031040A2 (da)
ZA (1) ZA200906960B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3088397B1 (en) * 2007-04-11 2019-04-10 Canbas Co. Ltd. Compounds that abrogate the cell cycle g2 checkpoint for use in the treatment of cancer
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US8236862B2 (en) * 2009-02-06 2012-08-07 University Of Southern California Therapeutic compositions comprising monoterpenes
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
CA2828833C (en) 2010-03-03 2020-11-03 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES2610425T3 (es) 2010-08-27 2017-04-27 Neonc Technologies Inc. Composiciones farmacéuticas que comprenden carbamatos de alcohol perilílico
CN103517892B (zh) 2010-12-17 2016-01-27 尼昂克技术公司 使用异紫苏醇的方法和装置
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
US9814693B2 (en) 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
CA2876382A1 (en) 2012-06-14 2013-12-19 Daiichi Sankyo Company, Limited Piperidinylpyrazolopyridine derivative
CA2899399A1 (en) 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
WO2016090355A2 (en) * 2014-12-05 2016-06-09 Massachusetts Institute Of Technology Catechol-rich polymers from n-substituted maleimides
HRP20230659T1 (hr) 2015-01-26 2023-10-13 Ottawa Hospital Research Institute Sastavi i metode za osjetljivost na viruse
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
JP2019513700A (ja) 2016-03-16 2019-05-30 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺有害生物剤及び植物保護剤としてのｎ−（シアノベンジル）−６−（シクロプロピル−カルボニルアミノ）−４−（フェニル）−ピリジン−２−カルボキサミド誘導体及び関連する化合物
USD801721S1 (en) 2016-03-31 2017-11-07 Patricia Grayson Briden Spooled item holding device
USD915100S1 (en) 2016-03-31 2021-04-06 Ocean 22, Llc Spooled item holding device
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
WO2019148181A1 (en) 2018-01-29 2019-08-01 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
CR20200332A (es) 2018-02-02 2020-09-03 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
CA3225993A1 (en) 2018-02-08 2019-08-15 University Of Southern California The use of monoterpene, sesquiterpene, or their derivatives to permeabilize the blood brain barrier
EP4153600A1 (en) 2020-05-22 2023-03-29 Boehringer Ingelheim International GmbH Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法
WO2023064888A1 (en) * 2021-10-15 2023-04-20 The Curators Of The University Of Missouri Inhibitors of p1b-type atpases
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5564557A (en) * 1978-11-08 1980-05-15 Mitsui Toatsu Chem Inc Diphenyl ether compound and herbicide containing the same
IL81307A0 (en) * 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US5635966A (en) * 1994-01-11 1997-06-03 Hewlett-Packard Company Edge feed ink delivery thermal inkjet printhead structure and method of fabrication
JPH07224032A (ja) 1994-02-09 1995-08-22 Mitsui Petrochem Ind Ltd Ｎ−アリールオキシフタルイミド誘導体、その製造方 法及びそれを有効成分として含有する除草剤
JPH07244032A (ja) * 1994-03-01 1995-09-19 Ishikawajima Harima Heavy Ind Co Ltd 溶接部検査装置
AU726058B2 (en) * 1995-09-01 2000-10-26 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2245029A1 (en) * 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6205557B1 (en) 1998-06-09 2001-03-20 At&T Corp. Redundant call processing
US6476061B1 (en) * 1998-11-24 2002-11-05 Basf Aktiengesellschaft Fungicides containing pyrrolidones as their active agents
ES2239037T3 (es) 1999-09-22 2005-09-16 Canbas Co., Ltd. Metodos y composiciones para inhibir la deteccion del ciclo celular en g2 y sensibilizar celulas a agentes dañinos del dna.
ATE279110T1 (de) * 2000-02-26 2004-10-15 Basf Ag Fungizide mittel enthaltend als wirkstoffe pyrrolidone und deren verwendung bei der behandlung von pflanzen
JP2002318434A (ja) * 2001-04-23 2002-10-31 Konica Corp ハロゲン化銀写真感光材料、処理方法、および画像形成方法
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7030111B2 (en) * 2002-06-06 2006-04-18 Canbas Co., Ltd. Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
US7572816B2 (en) * 2003-08-01 2009-08-11 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
EP1724263B1 (en) * 2004-03-10 2014-03-05 Kureha Corporation Basic amine compound and use thereof
CA2559866A1 (en) * 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
AU2006212951A1 (en) * 2005-02-08 2006-08-17 Merck & Co., Inc. Inhibitors of checkpoint kinases
WO2007022241A2 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity quinoline-based kinase ligands
CA2627910A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
US7994205B2 (en) * 2006-03-31 2011-08-09 Takeda Pharmaceutical Company Limited Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors
US20080221103A1 (en) * 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
EP3088397B1 (en) 2007-04-11 2019-04-10 Canbas Co. Ltd. Compounds that abrogate the cell cycle g2 checkpoint for use in the treatment of cancer

Also Published As

Publication number Publication date
MX2009011025A (es) 2010-01-25
CN105175394A (zh) 2015-12-23
IL289165B2 (en) 2024-05-01
CA3188320A1 (en) 2009-03-12
BRPI0810911A2 (pt) 2021-03-30
EP3088397A1 (en) 2016-11-02
ES2594704T3 (es) 2016-12-22
IL289165B1 (en) 2024-01-01
EP2152692B9 (en) 2020-03-25
CA3030510A1 (en) 2009-03-12
EP4074704A1 (en) 2022-10-19
BRPI0810911B1 (pt) 2022-05-17
BR122022005149B1 (pt) 2022-09-27
HUE029370T2 (hu) 2017-02-28
IL242883B (en) 2022-01-01
CN101720323A (zh) 2010-06-02
US20080275057A1 (en) 2008-11-06
RU2009141619A (ru) 2011-05-20
IL289165A (en) 2022-02-01
CA2684037A1 (en) 2009-03-12
KR101475311B1 (ko) 2014-12-23
RU2482111C2 (ru) 2013-05-20
HUE059861T2 (hu) 2023-01-28
NZ580237A (en) 2012-06-29
CA2684037C (en) 2016-02-16
ES2732230T3 (es) 2019-12-12
CA2913840A1 (en) 2009-03-12
KR20090128560A (ko) 2009-12-15
EP2152692B1 (en) 2016-06-15
WO2009031040A3 (en) 2009-05-14
EP3567035A1 (en) 2019-11-13
US8415357B2 (en) 2013-04-09
US8084454B2 (en) 2011-12-27
JP5635396B2 (ja) 2014-12-03
JP2010523644A (ja) 2010-07-15
AU2008294410A1 (en) 2009-03-12
AU2008294410B2 (en) 2012-09-06
HK1139143A1 (zh) 2010-09-10
CA2913840C (en) 2019-03-05
ZA200906960B (en) 2010-12-29
JP2014012706A (ja) 2014-01-23
MX2020009403A (es) 2022-03-31
ES2927954T3 (es) 2022-11-14
CA3030510C (en) 2023-03-14
IL201380A0 (en) 2010-05-31
EP2152692A2 (en) 2010-02-17
WO2009031040A2 (en) 2009-03-12
IL309201A (en) 2024-02-01
EP3088397B1 (en) 2019-04-10
EP3567035B1 (en) 2022-06-01
CN105175394B (zh) 2018-06-08
US20110092514A1 (en) 2011-04-21
DK3567035T3 (da) 2022-09-05

Similar Documents

Publication Publication Date Title
DK2152692T3 (da) Forbindelser med anti-cancer aktivitet
AU2017276457B2 (en) Novel heterocyclic derivatives useful as SHP2 inhibitors
CA3002416C (en) Benzimidazolyl derivatives for use as ferroportin inhibitors
WO2018177403A1 (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
BRPI0814958B1 (pt) Compostos de indol, e, composição
CN107176933B (zh) 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂
KR102014478B1 (ko) 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
EA037264B1 (ru) Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство
CN108689937B (zh) 吲唑类化合物及其在制备ido抑制剂类药物上的用途
WO2017025493A1 (en) Quinoline ezh2 inhibitors
CN107840826B (zh) 1h-吲唑类衍生物及其作为ido抑制剂的用途
WO2017152032A1 (en) Novel oxazole and thiazole compounds as β-catenin modulators and uses thereof
CN111875583B (zh) 三氮唑衍生物及其制备方法和用途